Anuh Pharma FY26 results: profit falls, revenue rises

Key takeaway from the FY26 audited numbers

Anuh Pharma Limited announced its audited financial results for FY26, showing a year-on-year decline in profitability even as revenue increased. Net profit for FY26 came in at ₹4,104.61 lakh, compared with ₹4,735.19 lakh in FY25. Revenue from operations rose to ₹77,165.74 lakh from ₹66,151.49 lakh in the previous year. The update places the focus on margins and cost control, because the top line expanded while net profit contracted. The company also communicated corporate actions around dividends and shareholder meetings alongside the results. For investors, these disclosures matter because they combine operating performance with capital return signals.

FY26 performance: revenue up, profit down

The FY26 revenue growth was sizeable in absolute terms, rising by ₹11,014.25 lakh from FY25 to FY26. At the same time, net profit declined by ₹630.58 lakh over the same period. This combination points to a year where either costs rose faster than revenue, or non-operating items reduced the bottom line, though the filing excerpt does not specify drivers. The company disclosed the headline audited figures, which are typically the starting point for market interpretation. The mix of improving operations and softer earnings often leads investors to look for management commentary in detailed results documents. In this case, the publicly shared points were limited to the key financials and board decisions.

Dividend recommendation and AGM date

Anuh Pharma’s board recommended a final dividend of ₹1.50 per share and scheduled the Annual General Meeting (AGM) for August 12, 2026. The dividend is a key part of shareholder return, and the AGM sets the formal timetable for approvals. Separately in the provided disclosures, the company also stated that a dividend of ₹1.50 per equity share was declared for FY 2024-25. Multiple mentions of the ₹1.50 per share final dividend indicate that this payout level is central to the company’s recent shareholder distributions. The disclosures note that such dividends are typically subject to shareholder approval at the AGM.

Corporate actions: bonus issue and post-bonus dividend disclosure

The company’s exchange filing also refers to the board considering and approving a bonus equity issue in the ratio 1:1. The bonus issue is described as 1 equity share of face value ₹5 each for every 1 fully paid-up equity share held, subject to shareholder approval via postal ballot. The record date for the bonus issue was to be announced later. In the same set of disclosures, Anuh Pharma informed exchanges that the board recommended a dividend of ₹1.50 per equity share on post-bonus share capital, described as a 30% payout on the face value of ₹5 each for the financial year ended March 31, 2025. The filing also states that bonus shares would be entitled to the proposed final dividend of ₹1.50 per share. These details are important for investors tracking entitlement timelines and how the bonus impacts per-share calculations.

Board meeting and event calendar references in filings

The text also includes a “Board Meeting Intimation” for consideration and approval of unaudited financial results for the quarter ended December 31, 2025. In the corporate action table provided, the ex-date for “Dividend - Rs 1.50 Per Share” is listed as 14-Aug-2025, while the ex-date for “Bonus 1:1” is listed as 15-Jul-2025. Additional board meeting entries reference dates such as 08-Aug-2025, 23-May-2025, and 07-Feb-2025, tied to consideration of financial results and other business matters. While the excerpt does not include the full meeting outcomes for each date, it indicates an active disclosure schedule. For market participants, these dates often matter for eligibility, record dates, and planning around corporate actions.

Snapshot: FY26 vs FY25, plus earlier FY25/FY24 context

Beyond FY26 audited numbers, the provided material also contains FY25 and quarterly performance indicators. For the year ending March 2025 (FY25), net profit is stated to have declined 21.16% to ₹4,735 lakh from ₹6,006 lakh in the year ending March 2024 (FY24). FY25 sales are stated to have increased by 2.24% to ₹66,151 lakh compared with ₹64,700 lakh in FY24. For the March 2025 quarter (Q4FY25), net profit is stated at ₹1,246 lakh versus ₹1,536 lakh in Q4FY24, while sales increased to ₹19,814 lakh from ₹16,389 lakh and EBITDA declined to ₹2,007 lakh from ₹2,205 lakh. These numbers provide a shorter-term view that aligns with the broader theme of revenue resilience but pressure on profitability.

Key numbers table (all amounts in ₹ lakh)

Dividend and bonus timeline references (as disclosed)

Market view cited in the disclosures

The provided material also includes a technical view attributed to A R Ramachandran, an independent research analyst. The comment states that Anuh Pharma’s stock price was “bullish but also overbought” on daily charts, with support at 180. It adds that a daily close above resistance of 217 could lead to a target of 244 in the near term. This is presented as an external market observation rather than a company statement. Readers should treat it as an analyst’s chart-based view rather than a confirmed outcome.

Why the FY26 update matters for investors

The FY26 results combine a strong revenue jump with lower net profit, which tends to shift investor attention to margin drivers, cost structure, and operating leverage. The repeat emphasis on a ₹1.50 per share dividend, along with an AGM date, also signals the company’s near-term shareholder-return agenda. The bonus issue references add another layer, because a 1:1 bonus can materially change the number of shares outstanding and affect per-share optics, even though it does not change underlying business value by itself. With multiple dated disclosures and corporate action references, investors typically track eligibility dates and approval requirements closely.

Conclusion

Anuh Pharma’s FY26 audited results show revenue growth to ₹77,165.74 lakh alongside a net profit decline to ₹4,104.61 lakh. The board’s recommended ₹1.50 per share final dividend and the AGM scheduled for August 12, 2026 set the next milestones for shareholder approvals. Separately, the company has also disclosed a 1:1 bonus issue proposal subject to shareholder approval via postal ballot, with the record date to be announced. The next set of clarity points for the market will come from detailed financial statements, AGM outcomes, and any further exchange filings on record dates and entitlements.